This is an old revision of this page, as edited by Jonowen008 (talk | contribs) at 19:12, 15 September 2010. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 19:12, 15 September 2010 by Jonowen008 (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.308.391  |
| Chemical and physical data | |
| Formula | C88H100Cl2N10O28 |
| Molar mass | 1755.634 g/mol g·mol |
Dalbavancin (INN, trade name Zeven) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely-used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).
It possesses in vitro activity against a variety of Gram-positive pathogens including MRSA and MRSE. It is a once-weekly, two-dose antibiotic that Pfizer acquired when it bought Vicuron Pharmaceuticals in 2005.
On September 9, 2008, Pfizer announced that it will withdraw all marketing applications in order to conduct another Phase 3 clinical trial.Dalbavancin (BI397) is a novel semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.
References and notes
- Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug Administration
- Chen AY, Zervos MJ, Vazquez JA (2007). "Dalbavancin: a novel antimicrobial". Int. J. Clin. Pract. 61 (5): 853–63. doi:10.1111/j.1742-1241.2007.01318.x. PMC 1890846. PMID 17362476.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Das B, Sarkar C, Biswas R, Pandey S (2008). "Review: dalbavancin-a novel lipoglycopeptide antimicrobial for gram positive pathogens". Pak J Pharm Sci. 21 (1): 78–88. PMID 18166524.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - Dalbavancin: A Novel Lipoglycopeptide Antibacterial
- UPDATE 1-Pfizer says US FDA wants more data on antibiotic
- "Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial" (Press release). Pfizer Inc. 2008-09-09. Retrieved 2008-09-11.
- Scheinfeld NS. Dalbavancin: A review for dermatologists. Dermatology Online Journal 12 (4): 6. PMID 17083861
 | This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it. |